Teva Pharm announces approval of Terbinafine HCL tablets

Co announces that the FDA has granted final approval for the co's Abbreviated New Drug Application to market Terbinafine Hydrochloride Tablets, 250 mg, the AB-rated generic equivalent of Novartis' antifungal agent Lamisil Tablets. Shipment of this product will begin immediately.

• Tweet this
• Link this
• Share this
• Digg this
• Email
• Reprints

Comments (0)

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.